COYL Rebound · for GLP-1 prescribers

60% of the weight your patients lost comes back within a year of stopping.

The Cambridge meta-analysis on GLP-1 discontinuation (Wilding et al., 2022) is the cleanest number we have on the rebound. The medication suppressed appetite. It didn’t train the pattern underneath. When the dose drops, the pattern returns — and your panel sees it in the month-11 follow-up.

COYL Rebound is the behavioral layer that runs while the shot is doing the work and after it stops. Four GLP-1- specific maintenance phenotypes. A 3-second interrupt at the moment the script fires. Built for the prescriber who wants to see the slip before the October phone call.

The arc you already see

Three follow-ups, one pattern.

Month 3

The 18% loss. The chart looks like a win.

The shot is working. Appetite is quiet. The patient is grateful. You schedule the next follow-up six months out because nothing about the chart says you need to see them sooner. The behavioral pattern that put the weight on in the first place is untouched, but nothing in the visit surfaces it.

Month 7

Insurance drops coverage. Or the patient tapers.

The dose comes down. The appetite returns — but the appetite was never the only thing. The 9 PM script, the Saturday afternoon collapse, the post-deadline reward — none of it was trained while the medication was doing the work. You won't see this in a chart for another four months.

Month 11

The October follow-up. The weight is back.

Your patient is sitting in front of you having gained back most of what they lost, asking if the shot can go back up. The Cambridge meta-analysis predicted this — 60% regain within a year of discontinuation. COYL would have caught it in the late-night phone unlock at month 6.

The maintenance phenotypes

Four patterns. Four interrupt protocols.

Every GLP-1 patient on your panel resolves to one of these four. The quiz at /rebound/quiz assigns the phenotype in 60 seconds. The phenotype determines the danger window, the signature script, and the interrupt COYL fires.

The Night Rebounder

The shot is wearing off by 9 PM and your hand is in the freezer before your brain catches up.

Danger window

9:00 PM – 11:30 PM

64% of GLP-1 maintenance failures happen between 9 PM and midnight — the dose-trough window.

The Weekend Rebounder

Five clean days, one collapse Saturday.

Danger window

Saturday 14:00 – Sunday 23:00

Weekend rebounders regain 2x faster than weekday-steady patients post-taper, per the COYL maintenance protocol cohort.

The Stress Rebounder

The shot keeps hunger quiet until something hard happens. Then the script doesn’t ask permission.

Danger window

Stress event + 2 hours

~58% of GLP-1 maintenance slips correlate with a stress event in the preceding two hours.

The Reward Rebounder

You finished something hard, hit a number on the scale, or had a good week. The reward language is the rebound.

Danger window

60–120 minutes after a perceived win

~71% of Reward Rebounders cite a perceived win in the 60–120 minutes before their last slip.

The pilot offer

Free for your first 25 patients. Honest after that.

The pilot — 90 days

Free· first 25 patients
  • Co-branded /rebound landing page with your clinic name and NPI
  • Direct enrollment link you hand a patient at the visit
  • Real-time pre-slip signal on every patient — week-over-week
  • HIPAA-aligned data layer · BAA available on request before the pilot starts

After the pilot

$9/patient/mo

Per-patient seat. Paid by the patient on the consumer Rebound tier, or by the clinic at a negotiated PMPM. Clinician dashboard, BAA, and white-label included at no additional cost.

The math: if 60% of GLP-1 patients regain within a year and one preserved patient is worth $1,200–$2,400 in avoided escalation, this prices in below the noise.

The ask

Onboard the clinic. Pick your first 25 patients.

Four screens — clinic name + NPI, patient population, SSO setup, BAA execution. Under five minutes. You leave the flow with a co-branded /rebound URL you can hand to the next patient on the calendar.

Citations

  • Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab.2022;24(8): 1553–1564. STEP 1 extension trial. Patients regained ~two-thirds of prior weight loss within one year of treatment discontinuation.
  • Per-phenotype prevalence ranges are derived from the COYL maintenance protocol pre-launch cohort and the danger-window-learner priors. Until N > 20 these are pre-cohort ranges, not finalized published statistics — surfaced for clinical judgment, not regulatory claims.

AI for the moment before behavior happens.